Another hepatitis C treatment option has been added to the Pharmaceutical Benefits Scheme (PBS).

Grazoprevir + Elbasvir (also known by its combined commercial name Zepatier), is recommended for genotypes 1 and 4.

The recommended treatment regimen for treatment-naive is 12 weeks and for treatment-experienced is either 12 weeks or 16 weeks with ribavirin.

For more information, visit http://www.pbs.gov.au/info/healthpro/explanatory-notes/general-statement-hep-c.